

(19)



(11)

EP 3 230 319 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) International Patent Classification (IPC):

C07K 16/28 ^(2006.01) **A61K 39/00** ^(2006.01)
A61P 35/00 ^(2006.01)

(48) Corrigendum issued on:

12.10.2022 Bulletin 2022/41

(52) Cooperative Patent Classification (CPC):
(C-Sets available)

A61K 39/3955; A61K 39/0011; A61P 1/02;
A61P 1/04; A61P 1/16; A61P 1/18; A61P 5/00;
A61P 11/00; A61P 13/08; A61P 13/10;
A61P 13/12; A61P 15/00; A61P 17/00;
A61P 19/00; A61P 21/00; (Cont.)

(45) Date of publication and mention of the grant of the patent:

07.09.2022 Bulletin 2022/36

(21) Application number: **15808464.0**

(86) International application number:
PCT/IB2015/059268

(22) Date of filing: **02.12.2015**

(87) International publication number:
WO 2016/092419 (16.06.2016 Gazette 2016/24)

(54) **ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF**

ANTI-PD-1-ANTIKÖRPER UND VERFAHREN ZU DEREN VERWENDUNG

ANTICORPS DIRIGÉS CONTRE LA PROTÉINE DE MORT PROGRAMMÉE 1 (PD-1)

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

- **JOOSS, Karin Ute**
San Diego, California 92106 (US)
- **RAJPAL, Arvind**
San Francisco, California 94127 (US)
- **YOUSSEF, Sawsan**
Menlo Park, California 94025 (US)

(30) Priority: **09.12.2014 US 201462089658 P**
16.10.2015 US 201562242750 P
06.11.2015 US 201562251973 P

(74) Representative: **Pfizer**
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 (FR)

(43) Date of publication of application:
18.10.2017 Bulletin 2017/42

(60) Divisional application:
22194128.9

(56) References cited:
WO-A1-2014/159562 WO-A2-2014/179664

(73) Proprietor: **Rinat Neuroscience Corp.**
New York, NY 10017 (US)

- (72) Inventors:
- **ABDICHE, Yasmina Noubia**
South San Francisco, California 94080 (US)
 - **CHO, Helen Kim**
San Diego, California 92130 (US)
 - **HO, Weihsien**
Belmont, California 94002 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 230 319 B8

(52) Cooperative Patent Classification (CPC): (Cont.)

A61P 25/00; A61P 35/00; A61P 35/02;
A61P 43/00; C07K 16/2818; C07K 16/2878;
A61K 2039/505; A61K 2039/507; A61K 2039/53;
A61K 2039/545; C07K 2317/24; C07K 2317/33;
C07K 2317/55; C07K 2317/74; C07K 2317/76;
C07K 2317/92; C07K 2317/94

C-Sets

A61K 39/3955, A61K 2300/00